Opendata, web and dolomites

AMPK-DIAB SIGNED

A small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novelinnovative drug for the treatment of type 2 diabetes

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AMPK-DIAB project word cloud

Explore the words cloud of the AMPK-DIAB project. It provides you a very rough idea of what is the project "AMPK-DIAB" about.

amp    drugs    betagenon    molecule    clinicians    insufficient    1980    complication    patients    metformin    iib    obese    resistance    clinical    fill    rate    arterial    market    energy    heart    individuals    nerve    glucose    strategically    primary    peripheral    plasma    treatment    regulator    t2    drug    class    validation    amputations    denoted    diabetes    obesity    first    world    damage    insulin    approx    outlicensing    epidemic    diabetics    fasting    validated    company    none    commercialize    lifestyle    hallmark    million    adults    free    422    date    blood    quadrupled    living    organism    economies    performing    activated    delivering    proof    add    regimen    iia    activator    protein    becomes    2014    efficient    t2d    diagnosed    gap    blindness    small    ampk    disease    validate    stable    kidney    middle    close    cell    reduces    calf    treatments    attack    muscle    candidate    90    aged    single    recommended    balance    people    complications    o304    line    kinase    hyperaemic    life    data    108    cardiovascular    threatens    stroke   

Project "AMPK-DIAB" data sheet

The following table provides information about the project.

Coordinator
BETAGENON AB 

Organization address
address: TVISTEVAGEN 48C
city: UMEA
postcode: 907 36
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://betagenon.se/
 Total cost 2˙604˙625 €
 EC max contribution 1˙823˙237 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BETAGENON AB SE (UMEA) coordinator 1˙823˙237.00

Map

 Project objective

This project aims to close the gap to the market for a small molecule AMP activated protein kinase (AMPK) activator, denoted O304, as a novel first-in-class drug for the treatment of type 2 diabetes (T2D) and associated cardiovascular complications, including heart failure and peripheral arterial disease.

The number of adults around the world with diabetes quadrupled from 108 million in 1980 to 422 million in 2014. About 90% of these people have type 2 diabetes — a major cause of kidney failure, blindness, nerve damage, amputations, heart attack and stroke. It is estimated that only approx. 10 % of T2 diabetics reach the goal of living a complication free life. Today, patients diagnosed with T2D are recommended a change in lifestyle and the drug Metformin is the first line of treatment. When Metformin becomes insufficient, a number of add-on treatments are used, including insulin. None of the existing drugs, however, reduces insulin resistance - a primary cause of obesity-induced T2D.

Betagenon has developed and pre-validated the first candidate AMPK activator drug in T2 diabetics, a key regulator of energy balance, both on a single cell level and the whole organism level. Phase I clinical data show that O304 reduces fasting plasma glucose, the hallmark of T2D, in patients with T2D on stable metformin treatment, and increases the rate of hyperaemic blood in calf muscle in middle aged obese individuals. The project is strategically focused on performing a Phase IIa proof-of-concept validation of O304. This will enable Betagenon to commercialize the product through outlicensing to a Phase IIb and Phase III validation partner.

Diabetes is an epidemic that threatens the economies of all EU member states. The project addresses this challenge by delivering a novel drug treatment regimen to clinicians and their patients. O304 will fill the knowledge gap on the EU level, as to date no company has been able to pre-validate an efficient small molecule AMPK activator.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AMPK-DIAB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AMPK-DIAB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

sFilm-FS (2018)

Fibrin sealant for anastomotic leaks and haemostasis

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More